View
3
Download
0
Category
Preview:
Citation preview
1
Ligand-dependent interaction of PPARδ with T cell protein tyrosine
phosphatase 45 enhances insulin signaling
Taesik Yoo1, Sun Ah Ham
1, Won Jin Lee
1, Seon In Hwang
2, Jin-A Park
3, Jung Seok Hwang
1,
Jinwoo Hur1, Ho-Chul Shin
3, Sung Gu Han
1, Chi-Ho Lee
1, Dong Wook Han
2, Kyung Shin
Paek4, and Han Geuk Seo
1,5
1 Sanghuh College of Life Sciences, Konkuk University, Seoul, Korea;
2 Department of Stem Cell Biology, Konkuk University, Seoul, Korea;
3 Department of Veterinary Pharmacology and Toxicology, Konkuk University, Seoul, Korea;
4 Department of Nursing, Semyung University, Jechon, Korea.
5 Correspondence to:
Han Geuk Seo, Sanghuh College of Life Sciences, Konkuk University, 120 Neungdong-
ro, Gwangjin-Gu, Seoul 05029, Republic of Korea.
Tel.: +82-2-450-0428, Fax: +82-2-455-1044, E-mail: hgseo@konkuk.ac.kr
Running title: TCPTP45-mediated insulin sensitization of PPARδ
Page 1 of 55 Diabetes
Diabetes Publish Ahead of Print, published online December 12, 2017
2
ABSTRACT
Peroxisome proliferator-activated receptor (PPAR) δ plays a pivotal role in metabolic
homeostasis through its effect on insulin signaling. Although diverse genomic actions of
PPARδ are postulated, the specific molecular mechanisms whereby PPARδ controls insulin
signaling have not been fully elucidated. We demonstrate here that short-term activation of
PPARδ results in formation of a stable complex with nuclear T cell protein tyrosine
phosphatase 45 (TCPTP45) isoform. This interaction of PPARδ with TCPTP45 blocked
translocation of TCPTP45 into the cytoplasm, thereby preventing its interaction with the
insulin receptor, which inhibits insulin signaling. Interaction of PPARδ with TCPTP45
blunted interleukin 6-induced insulin resistance, leading to retention of TCPTP45 in the
nucleus, thereby facilitating deactivation of the STAT3-SOCS3 signal. Finally, GW501516-
activated PPARδ improved insulin signaling and glucose intolerance in high-fat diet-fed mice
through its interaction with TCPTP45. This novel interaction of PPARδ constitutes the most
upstream component identified of the mechanism downregulating insulin signaling.
Keywords: GW501516, insulin, PPARδ, protein-protein interaction, TCPTP45
Page 2 of 55Diabetes
3
Insulin initiates its cellular actions by binding to its cell surface transmembrane receptor,
which is a tyrosine kinase (1). Upon binding of insulin to the extracellular α-subunit, the
intrinsic protein tyrosine kinase (PTK) activity of the intracellular β-subunit is activated,
leading to its autophosphorylation and subsequent phosphorylation of insulin receptor
substrate (IRS) proteins and other adaptor molecules (2). This tyrosine phosphorylation
provides docking sites for the recruitment of several src homology 2 domain-containing
proteins, such as the p85 regulatory subunit of phosphatidylinositol 3-kinase (PI3K), which
mediate the biological activities of insulin in its target organs (2,3). Under the pathological
conditions associated with obesity and type 2 diabetes, impaired responses to insulin are
coupled with resistance to its actions in target organs, including liver, muscle, and adipose
tissue (3).
Evidence is emerging that protein tyrosine phosphatases (PTPs) play a pivotal role in
insulin receptor (IR) signaling, by dephosphorylating the IR within minutes of its activation,
to terminate IR-mediated insulin signaling (4,5). Both T cell protein tyrosine phosphatase
(TCPTP) and PTP1B are implicated as negative regulators of IR (4,6), but they have distinct
biological activities, by virtue of their substrate specificity and different subcellular locations
(4). TCPTP, which was originally identified in human T cells (7), has two alternative splice
variants: a 48 kDa form (TCPTP48), which contains a hydrophobic carboxy-terminus and is
localized to the endoplasmic reticulum (ER), similar to PTP1B, and a shorter 45 kDa form
(TCPTP45), which lacks the hydrophobic C-terminus and is targeted to the nucleus (8).
Although TCPTP45 is localized to the nucleus in resting cells, it is translocated to the
cytoplasm and plasma membrane in response to external stimuli such as insulin, where it can
access its substrates (9). Accordingly, TCPTP45 can dephosphorylate the IR in the cytoplasm
and at the plasma membrane, whereas ER-targeted TCPTP48 dephosphorylates the IR after it
Page 3 of 55 Diabetes
4
has been endocytosed, similar to the action of PTP1B (5,9). In addition to utilizing receptor
PTKs, such as IR, as substrates, TCPTP also utilizes non-receptor PTKs as substrates,
including signal transducer and activator of transcription (STAT)-3 (10,11). Indeed, recent
studies demonstrated that STAT3, a target of TCPTP45, is implicated in the insulin resistance
induced by interleukin 6 (IL-6), through upregulation of suppressor of cytokine signaling 3
(SOCS3), which contributes to the negative regulation of insulin signaling by interacting with
the IR and IRS (12).
The biological activity of peroxisome proliferator-activated receptor (PPAR) δ, a nuclear
receptor, has been credited to transcriptional programs that regulate the expression of target
genes (the so-called genomic action) (13,14). However, there have been recent reports that
could not explain the biological functions of PPARδ by a genomic action alone (15,16). Here,
we report that short-term activation of PPARδ by high-affinity ligand results in the formation
of a stable complex with TCPTP45, thereby blocking the insulin-responsive translocation of
nuclear TCPTP45 into the cytoplasm, and preventing access of TCPTP45 to IR and its
inhibitory effect on insulin signaling. In addition, this protein-protein interaction blunts IL-6-
induced insulin resistance by accelerating TCPTP45-mediated deactivation of the STAT3-
SOCS3 signal, in a process mediated by sequestration of TCPTP45 within the nuclear
compartment. These observations demonstrate the role of a novel TCPTP45-mediated
pathway in the insulin sensitizing action of PPARδ.
Page 4 of 55Diabetes
5
RESEARCH DESIGN AND METHODS
Co-immunoprecipitation and immunoblot analysis
Cell and tissue lysates were prepared and then pre-cleared with protein G Sepharose. Pre-
cleared lysates were mixed with the specified antibodies and then precipitated with protein G
Sepharose. After washing with PBS, the immunoprecipitates and total lysates (input) were
subjected to immunoblot analysis.
Animal study
Male ICR mice (4-week-old, 15–20 g) were purchased from Orient Bio (Seongnam, Korea)
and maintained in pathogen-free environmental conditions on a 12 h light-dark cycle at 22 ±
2 °C. All procedures were approved by the Institutional Animal Care and Use Committee of
Konkuk University (approval number: KU16144). After 1 week of acclimation, the mice
were divided into two groups, and were fed either a normal diet (ND) (Altromin Spezialfutter
GmbH & Co., Lage, North Rhine-Westphalia, Germany) or a high-fat diet (HFD) (Research
Diets, Inc. NJ, USA) for 10 weeks, during which water and diet were available ad libitum.
Glucose and insulin tolerance tests
For intraperitoneal glucose tolerance testing (IPGTT), mice were fasted for 16 h, and then
glucose (2 g/kg body mass) was administered intraperitoneally. Blood was taken from the tail
vein at 0, 30, 60, 90, and 120 min after glucose injection, and the circulating glucose levels
were determined using a OneTouch automatic glucose monitor (LifeScan, Inc., Milpitas, CA,
USA). For intraperitoneal insulin tolerance testing (IPITT), insulin (0.5 units/kg of body mass)
in sterile saline was injected intraperitoneally, and the circulating glucose levels were
determined as described above.
Page 5 of 55 Diabetes
6
Statistical analysis
Data are expressed as mean ± standard error (SE). Statistical significance was determined by
one-way ANOVA, followed by Tukey-Kramer or Student’s t-test, as appropriate.
Page 6 of 55Diabetes
7
RESULTS
PPARδ directly interacts with TCPTP45
In a yeast-hybrid assay that used PPARδ as bait, we identified a cDNA fragment encoding a
full-length amino acid sequence of TCPTP45 in a universal human cDNA library. The
interaction of PPARδ with TCPTP45 was confirmed by co-immunoprecipitation assays
performed in primary hepatocytes, hepatoblastoma-derived HepG2 cells, differentiated
C2C12 myotubes, and 3T3-L1 adipocytes. When cells were treated with GW501516, a
specific PPARδ agonist, immunoprecipitation of PPARδ from whole-cell lysates resulted in
the co-immunoprecipitation of TCPTP45. However, PTP1B, another tyrosine-specific
phosphatase that targets the insulin receptor β-subunit (IRβ), was not co-immunoprecipitated
with PPARδ (Fig. 1A–D). This GW501516-dependent interaction was almost completely
abolished in HepG2 cells stably expressing PPARδ small hairpin (sh)RNA, indicating that
ligand-dependent activation of PPARδ is a prerequisite for its interaction with TCPTP45 (Fig.
1E and Supplementary Fig. 1A). This interaction of PPARδ with TCPTP45 was also
confirmed using reciprocal antibodies for immunoprecipitation and immunoblotting (Fig. 1F).
No proteins were immunoprecipitated using control immunoglobulin G (IgG). Similar results
were obtained in HEK293T cells co-transfected with Flag-tagged PPARδ and hemagglutinin
(HA)-tagged TCPTP45, in which the GW501516-dependent interaction of PPARδ and
TCPTP45 was present at 30 min and reached a maximum at 45 min (Fig. 1G and
Supplementary Fig. 1B). In addition, when HEK293T cells were transfected with individual
plasmids expressing PPARα, δ, or γ, together with TCPTP45, in the presence or absence of
specific ligands for each PPAR isoform, PPARδ but not PPARα and γ demonstrated a strong
Page 7 of 55 Diabetes
8
interaction with TCPTP45 in a co-immunoprecipitation assay, indicating that only the PPARδ
isoform can interact with TCPTP45 (Supplementary Fig.1C).
The bipartite nuclear localization sequence (NLS) of TCPTP45 is responsible for its
interaction with PPARδ
A direct interaction between PPARδ and TCPTP45 was further confirmed in glutathione S-
transferase (GST) pull-down assays, in which the majority of PPARδ was pulled down with
GST-fused TCPTP45 in the presence of GW501516 (Fig. 2A). Thus, we generated a panel of
TCPTP45 deletion mutants to identify the regions of TCPTP45 that are responsible for its
interaction with PPARδ (Fig. 2B). Whereas full-length TCPTP45 (FL) displayed a strong
interaction with PPARδ, the deletion mutants TCPTP45 (D1) and TCPTP45 (D2) showed no
significant interaction, indicating that the C-terminal region of TCPTP45 is essential for this
interaction (Fig. 2C). Because the C-terminal region of TCPTP45 has a bipartite nuclear
localization sequence (NLS), we constructed three NLS mutants to identify the critical amino
acid residue(s) responsible for the association of TCPTP45 with PPARδ. Site-directed
mutants were constructed by introducing amino acid substitutions in the N-terminal part of
NLS residues 350, 351, and 352 of TCPTP45 (TCPTP45350-A3
), and further substitutions in
the C-terminal part of NLS residues 378, 379, and 380 (TCPTP45378-A3
), and in both the N-
and C-terminal parts of NLS residues 350, 351, 352, 378, 379, and 380 (TCPTP45350/378-A3
),
replacing arginine or lysine residues with alanine (Fig. 2D).
When these mutant proteins were individually incubated with lysates prepared from
HEK293T cells that had been transfected with PPARδ, TCPTP45350-A3
displayed a weaker
ability than TCPTP45378-A3
to interact with PPARδ. Furthermore, the interaction between
PPARδ and TCPTP45 was nearly eliminated when PPARδ was incubated with
Page 8 of 55Diabetes
9
TCPTP45350/378-A3
, indicating that the bipartite NLS of TCPTP45 is indispensable for the
interaction with PPARδ (Fig. 2E). Consistent with this, the localization of TCPTP45 was
limited to the cytoplasm of HepG2 cells transfected with HA-tagged TCPTP45350/378-A3
(Fig.
2F).
Because TCPTP48 also has a bipartite NLS region, we examined the association
between PPARδ and TCPTP48 in HepG2 by co-immunoprecipitation. As expected, PPARδ
interacted with TCPTP48, suggesting that such protein-protein interactions via bipartite NLS
region may occur non-specifically under any conditions in which these molecules come into
close proximity by cellular destruction (Supplementary Fig. 2A). However, when the nuclear
or cytoplasmic fractions of HepG2 cells stimulated with GW501516 were analyzed to
confirm the specificity of TCPTP, an interaction between PPARδ and TCPTP was observed
in both fractions (Supplementary Fig. 2B and C). These results indicate that, although both
TCPTP45 and TCPTP48 can interact with PPARδ via their bipartite NLS, their subcellular
location is a unique determinant for a specific interaction with PPARδ.
To further evaluate the specificity of the bipartite NLS of TCPTP45 in the interaction
with PPARδ, the bipartite NLS of TCPTP45 was replaced with SV40 large T antigen NLS
(17). When the cells were transfected with TCPTP45350/378-SV40
, although the majority of
TCPTP45350/378-SV40
was observed in nuclear fraction, the interaction between PPARδ and
TCPTP45350/378-SV40
was not detected in the presence of GW501516 (Supplementary Fig. 2D-
F).
GW501516-activated PPARδ inhibits the insulin-triggered translocation of TCPTP45
from nucleus to cytoplasm
Because PPARδ interacted with both TCPTP45 and TCPTP48 in lysates prepared from
Page 9 of 55 Diabetes
10
HepG2 cells, we examined the cellular co-localization of PPARδ and TCPTPs to confirm the
exact nature of the interaction with PPARδ. By confocal fluorescence microscopy using
fluorescent fusion protein versions of PPARδ and TCPTP45D182A
or TCPTP48D182A
, which
are substrate-trapping mutants that can form complexes with tyrosine-phosphorylated
substrates (18), we observed that green fluorescent protein (GFP)-tagged PPARδ was co-
localized with Discosoma sp. red fluorescent protein (DsRed)-tagged TCPTP45 in the
nucleus of Chinese Hamster Ovary cells stably expressing the insulin receptor (CHO-IR).
Upon stimulation with insulin, the majority of DsRed-TCPTP45 was rapidly translocated into
the cytoplasm, but this insulin-stimulated translocation was almost completely abolished in
cells treated with GW501516 (Supplementary Fig. 3A). By contrast, neither co-localization of
GFP-PPARδ and DsRed-TCPTP48, nor translocation between intracellular compartments,
was observed, stressing the importance of subcellular localization in the interaction between
PPARδ and TCPTP45 (Supplementary Fig. 3B).
To investigate whether GW501516-activated PPARδ affects the insulin-stimulated
interaction of TCPTP45 with IRβ, co-immunoprecipitation assays were performed using
Flag-PPARδ and HA-TCPTP45D182A
in CHO-IR and HepG2 cells. Upon stimulation with
insulin, IRβ was co-immunoprecipitated with TCPTP45D182A
in both cells, whereas an
interaction between PPARδ and TCPTP45D182A
was not observed in the absence of
GW501516. By contrast, insulin-stimulated complex formation between IRβ and
TCPTP45D182A
was reduced in cells treated with GW501516, because of increased interaction
between PPARδ and TCPTP45D182A
. Furthermore, GSK0660-mediated antagonism of
GW501516 caused the dissociation of PPARδ and TCPTP45D182A
, with a concomitant
increase in the formation of IRβ and TCPTP45D182A
complexes (Fig. 3A and B). Similar
results were obtained from HepG2 cells stably expressing PPARδ or control shRNA (Fig.
Page 10 of 55Diabetes
11
3C). As expected, insulin-stimulated translocation of TCPTP45D182A
from the nucleus to the
cytoplasm was almost completely abolished in the presence of GW501516 with a
concomitant reduction in the interaction of TCPTP45D182A
and phosphorylated IRβ, and this
GW501516-mediated inhibition of TCPTP45D182A
translocation and interaction with IRβ was
prevented by GSK0660 (Fig. 3D).
The GW501516-stimulated interaction of PPARδ with TCPTP45 potentiates the insulin
signal
Because GW501516 induced an interaction between PPARδ and TCPTP45, particular
attention was paid to the effect on insulin signaling, because TCPTP45 can antagonize insulin
signaling by dephosphorylating IRβ (5). When HepG2 cells were treated with insulin, IRβ
was rapidly phosphorylated, and this effect was further potentiated in the presence of
GW501516 (Fig. 4A). This GW501516-mediated potentiation of IRβ phosphorylation was
almost completely abolished in HepG2 cells transfected with TCPTP45350/378-A3
, a site-
directed mutant lacking the molecular regions that interact with PPARδ (Fig. 4B). Consistent
with these results, GW501516-mediated potentiation of IRβ phosphorylation was also
manifested in cells that transiently expressed TCPTP45, but not TCPTP48 (Fig. 4C).
Furthermore, small interfering (si)RNA-mediated silencing of TCPTP, but not PTP1B,
prevented the effect of GW501516 to potentiate IRβ phosphorylation (Fig. 4D and
Supplementary Fig. 4A). Similar results are shown in primary hepatocytes (Fig. 4E).
GW501516-activated PPARδ extends the duration of insulin-stimulated IRβ
phosphorylation
When HepG2 cells were exposed to insulin, IRβ phosphorylation peaked after 2–5 min, and
Page 11 of 55 Diabetes
12
then rapidly returned to basal levels. However, pretreatment with GW501516 for 30 min
sustained IRβ phosphorylation until 60 min after the initial insulin exposure (Fig. 4F and H).
This effect of GW501516 on the duration of IRβ phosphorylation was further potentiated in
cells ectopically expressing PPARδ (Fig. 4G and H, and Supplementary Fig. 4B and C). This
effect of GW501516 remained significant for as long as 6 h in cells expressing PPARδ
(Supplementary Fig. 4D). Although this effect of GW501516 on IRβ phosphorylation was
prevented by shRNA-mediated silencing of PPARδ (Fig. 4I-K), it was rescued by ectopic
overexpression of PPARδ in transfectants stably expressing PPARδ shRNA (Fig. 4L-N). By
contrast, treatment with WY14643 or rosiglitazone, specific ligands for PPARα and PPARγ,
respectively, did not affect insulin-stimulated phosphorylation of IRβ (Supplementary Fig. 4E
and 4F).
GW501516-activated PPARδ regulates IRβ phosphorylation in a TCPTP45-dependent
manner
Ectopic expression of TCPTP45 inhibited the effect of GW501516 on IRβ phosphorylation in
cells stably expressing PPARδ shRNA but not control shRNA, while this effect of
GW501516 was rescued by ectopic expression of PPARδ (Fig. 5A and Supplementary Fig.
5A). Furthermore, The GW501516-stimulated interaction between PPARδ and TCPTP45
demonstrated in PPARδ precipitates was clearly correlated with increased phosphorylation of
IRβ (Fig. 5B). However, this effect of GW501516 was almost completely abolished in the co-
immunoprecipitate of TCPTP45350/378-A3
, indicating that the GW501516-stimulated
interaction of PPARδ with TCPTP45 prevents the access of TCPTP45 to cytoplasmic
tyrosine-phosphorylated IRβ (Fig. 5C).
Page 12 of 55Diabetes
13
The GW501516-stimulated interaction of PPARδ with TCPTP45 influences downstream
IR signaling
IR signaling has its biological effects in target organs through phosphorylation of intracellular
effector molecules such as IRS-1 and Akt (2). Consistent with the effect of GW501516 on
IRβ phosphorylation, GW501516 treatment prolonged the duration of insulin-stimulated IRS-
1 and Akt phosphorylation for 6 h in HepG2 cells stably expressing control shRNA
(Supplementary Fig. 5B), while these effects of GW501516 were dramatically inhibited in the
presence of PPARδ shRNA (Fig. 5D). In addition, the GW501516-stimulated interaction of
PPARδ with TCPTP45 observed in PPARδ precipitates was correlated with the increased
phosphorylation of IRS-1 and Akt, while these effects of GW501516 were almost completely
abolished when TCPTP45350/378-A3
was co-immunoprecipitated, indicating that the interaction
between PPARδ and TCPTP45 directly correlates with IRS-1 and Akt phosphorylation (Fig.
5E).
We next assessed glucose levels in the HepG2 cells, to evaluate whether GW501516-
mediated activation of PPARδ is directly coupled to the biological effects of insulin. Upon
exposure to insulin for 30 min, glucose levels in the glucose production medium dramatically
decreased, and this reduction in glucose output was further enhanced by treatment with
GW501516 in HepG2 cells stably expressing control shRNA. However, this effect of
GW501516 on glucose levels in the glucose production medium was significantly inhibited in
cells stably expressing PPARδ shRNA (Fig. 5F).
GW501516-activated PPARδ regulates insulin signaling in myotubes and adipocytes
Because skeletal muscle and adipocytes are also major target organs of insulin action (1), we
investigated the effect of GW501516 on insulin signaling in differentiated mouse C2C12
Page 13 of 55 Diabetes
14
myotubes and 3T3-L1 adipocytes. Consistent with the results observed in HepG2 cells,
GW501516 also increased the duration of IRβ and Akt phosphorylation by promoting
interaction between PPARδ and TCPTP45 (Fig. 6A and B, and Supplementary Fig. 6A and
B). Similar results were also observed in C2C12 myotubes transfected with epitope-tagged
PPARδ and TCPTP45, while the effects of GW501516 on the interaction of PPARδ with
TCPTP45 and insulin signaling were almost completely abolished in C2C12 myotubes
transfected with epitope-tagged PPARδ and TCPTP45350/378-A3
(Supplementary Fig. 6C).
Furthermore, insulin-induced translocation of Glut4 to the plasma membrane was sustained
for 6 h in cells treated with both insulin and GW501516, whereas the Glut4 signal was
predominantly cytoplasmic in cells treated with insulin alone at this time point (Fig. 6C and
D).
The GW501516-stimulated interaction between PPARδ and TCPTP45 mitigates IL-6-
induced insulin resistance
Since obesity-associated chronic inflammation of adipose tissue leads to insulin resistance in
peripheral tissues, including liver, and TCPTP45 is implicated in glucose homeostasis
through STAT3 signaling in liver (10,19), we examined the effects of GW501516 on IL-6-
induced insulin resistance. Insulin enhanced the phosphorylation of IRS-1 and Akt in HepG2
cells, but the insulin-stimulated phosphorylation of IRS-1 and Akt was markedly attenuated
in the presence of IL-6. However, this IL-6-mediated suppression of IRS-1 and Akt
phosphorylation was reversed by GW501516, implying a possible role for PPARδ in the
antagonism of inflammation-induced insulin resistance (Fig. 6E).
Because STAT3 and SOCS3 are implicated in IL-6-induced insulin resistance (12,20),
we examined the effects of GW501516 on the activation and expression of STAT3 and
Page 14 of 55Diabetes
15
SOCS3. Although insulin-stimulated phosphorylation of STAT3 and expression of SOCS3
were inhibited in HepG2 cells stably expressing control shRNA in the presence of
GW501516, these effects of GW501516 were substantially prevented by the expression of
PPARδ shRNA (Fig. 6F). Consistent with these results, siRNA-mediated knockdown of
SOCS3 prevented the IL-6-triggered suppression in the phosphorylation of IRS-1 and Akt,
indicating that SOCS3 plays a role in the GW501516-dependent modulation of insulin
resistance induced by IL-6 (Supplementary Fig. 6D). In addition, GW501516-stimulated
interaction between PPARδ and TCPTP45 observed in PPARδ precipitates was directly
correlated with the increased phosphorylation of Akt, with concomitant reductions in the
levels of STAT3 phosphorylation and SOCS3 expression. However, these effects of
GW501516 were significantly blunted in cells transfected with TCPTP45350/378-A3
instead of
TCPTP45, indicating that the GW501516-stimulated interaction of PPARδ with TCPTP45
improves IL-6-induced insulin resistance by targeting STAT3 and SOCS3 (Fig. 6G). Similar
results were also observed in primary hepatocytes (Fig. 6H).
Administration of GW501516 enhances insulin signaling in animal models
We next wished to evaluate whether GW501516-activated PPARδ can affect glucose
metabolism in ND- or HFD-fed mice. In follow-up experiments, we fed mice a ND or HFD
for 10 weeks and checked their body masses weekly to confirm the expected effect of HFD
feeding (Supplementary Fig. 7A). When mice were administered with GW501516 or DMSO
and challenged 30 min later with a bolus of glucose by intraperitoneal injection, blood
glucose levels of ND- or HFD-fed mice rapidly increased, to peak 30 min later. However,
blood glucose subsequently decreased more rapidly in HFD-fed mice that had been
administered with GW501516 than in those that had not (Fig. 7A). Analogous results were
Page 15 of 55 Diabetes
16
obtained in HFD-fed mice subjected to IPITT, in which the insulin-stimulated decrease in
blood glucose was greater following GW501516 administration (Fig. 7B).
To determine whether the administration of GW501516 directly affected the interaction
between PPARδ and TCPTP45, leading to an improvement of insulin signaling in vivo, we
analyzed the interaction by co-immunoprecipitation in lysates prepared from liver, skeletal
muscle, and adipose tissue. The interaction between PPARδ and TCPTP45 was greatest in the
tissues of ND-fed mice administered with GW501516, with a lesser effect of GW501516
being detected in HFD-fed mouse tissues. This GW501516-mediated enhancement in the
PPARδ/TCPTP45 interaction was closely correlated with the phosphorylation levels of IRβ
and Akt in these tissues (Fig. 7C-E). Interestingly, the circulating levels of insulin, glucose,
and IL-6 were significantly higher in HFD-fed mice than in ND-fed mice, but the levels of
insulin and glucose were significantly lower in mice treated with GW501516 for 30 min (Fig.
7F and G, and Supplementary Fig. 7C), implying an important role for PPARδ in insulin
action and whole body glucose homeostasis in vivo.
Page 16 of 55Diabetes
17
DISCUSSION
Short-term activation of PPARδ modulates IR signaling by preventing translocation of the IR-
specific phosphatase TCPTP45 into the cytoplasm because of their direct protein-protein
interaction. Unlike the genomic action of the transcription factor PPARδ, little is known
about non-genomic actions of PPARδ, such as its protein-protein interactions. Based on the
concept that PPARδ exerts its biological actions by regulating the transcription of target genes
(13), recent studies demonstrated that ligand-activated PPARδ improves insulin signaling
through transcriptional regulation of target genes such as insulin-induced gene-1, pyruvate
dehydrogenase kinase 4, and angiopoietin-like protein 4 in hepatocytes and myotubes (21,22).
In the most recent reports, cells were treated with specific PPARδ ligands for as long as
18 to 24 h, so that the effect of PPARδ activation on transcriptional programs and
downstream biological activities could be investigated (23,24). However, we show herein that
the activation of PPARδ by GW501516 for a period of only 30 min was sufficient to
phosphorylate IRβ and consequently IRS-1 and Akt. To achieve this effect, GW501516
promoted the interaction of PPARδ with TCPTP45, but could not affect the transcription of
TCPTP45. These findings suggest that non-genomic actions of PPARδ, rather than its
genomic actions, are important for the regulation of IR signaling. Thus, we propose a novel
mechanism whereby PPARδ influences insulin signaling, involving the sequestration of
PPARδ in the nucleus secondary to a protein-protein interaction with the IRβ-specific
phosphatase TCPTP45, therefore preventing binding to its cytoplasmic substrate IRβ.
Although GW501516-activated PPARδ interacted with both TCPTP45 and TCPTP48, it
co-localized in the nucleus with TCPTP45, but not TCPTP48. These two alternative splice
variants exhibit distinct subcellular localizations because of a difference in the seven amino
Page 17 of 55 Diabetes
18
acid residues at their carboxy-terminals. As a result, TCPTP48 is mainly localized to the ER,
while TCPTP45 is restricted to the nucleus in resting cells (9). Therefore, TCPTP48
dephosphorylates IRβ after it is endocytosed into the ER in response to insulin, whereas
TCPTP45 dephosphorylates IRβ in the cytoplasm and at the plasma membrane after its
translocation from the nucleus (6,9). In this context, the PPARδ-mediated prevention of
TCPTP45 translocation, but not that of TCPTP48, into the cytoplasm may contribute to the
enhancement in insulin signaling. GW501516-activated PPARδ also did not interact with
PTP1B, another tyrosine-specific phosphatase that targets IRβ in the ER (4,6). Thus, the
subcellular localization, as well as the other biochemical properties of the substrate, when
interacting with PPARδ, may be critical determinants of the effects of PPARδ on insulin
signaling.
PPARδ, but not PPARα or γ, specifically interacted with TCPTP45 in a ligand-
dependent manner to enhance insulin signaling. Previous studies demonstrated that specific
ligands for PPARγ enhance insulin signaling through genomic actions regulating gene
transcription, including that of adipocyte P2 (aP2), lipoprotein lipase (LPL), fatty acid-
transport protein (FATP), Glut4, glucokinase, uncoupling protein (UCP)-2 and UCP-3, to
regulate glucose homeostasis, adipocyte differentiation, and lipid storage in cell or animal
models (25,26). In addition, ligand-activated PPARα also ameliorated insulin resistance by
upregulating genes encoding FATP, acyl-CoA oxidase, and LPL, leading to increased hepatic
fatty acid uptake and lipid metabolism (27,28). These findings are consistent with the data
reported here, because both enhance insulin signaling, but the underlying mechanisms
mediating this effect are PPAR isoform-specific. Indeed, only a 30 min treatment with
GW501516 was sufficient to activate PPARδ and enhance insulin signaling by inhibiting
translocation of the IRβ-specific phosphatase TCPTP45 into the cytoplasm. This was the
Page 18 of 55Diabetes
19
result of a direct interaction with TCPTP45, which we term a non-genomic action here.
Consequently, the effect of each PPAR nuclear receptor on insulin signaling can be
characterized according to its genomic and/or non-genomic actions.
Although the present findings are consistent with previous reports that GW501516-
activated PPARδ ameliorates IL-6-induced insulin resistance in hepatocytes by inhibiting the
STAT3-SOCS3 pathway (29), the molecular mechanisms may differ between studies, because
30 min treatment with GW501516 was sufficient to inactivate the STAT3-SOCS3 pathway in
this study. Several recent studies demonstrated that activation of PPARδ by specific ligands
alleviated IL-6-induced insulin resistance by suppressing SOCS3 expression, secondary to
inhibition of STAT3 activation. These effects of GW501516 were observed in hepatocytes
and adipocytes treated for 24 h, suggesting that the effects of PPARδ in this context may be
principally dependent on its genomic activity (30,31). Indeed, TCPTP45 was reported to
inhibit IL-6-induced STAT3 phosphorylation, leading to the attenuation of insulin signaling in
the liver (10,11). Consistent with these reports, PPARδ-mediated retention of TCPTP45 in the
nucleus facilitated the access of TCPTP45 to its substrate STAT3, resulting in reduced IL-6-
mediated phosphorylation and suppression of STAT3-mediated SOCS3 expression, which is
linked to insulin resistance (19,29). Thus, the insulin sensitizing effects of GW501516 may
be collectively mediated by the interaction between PPARδ and TCPTP45.
As opposed to our present findings showing TCPTP45-dependent effect of PPARδ in
insulin signaling, a previous study demonstrated that TCPTP deficiency in muscle has no
effect on insulin signaling and glucose homeostasis (32). Although this discrepancy for
TCPTP action in muscle insulin signaling is not fully elucidated at present, our present data
evenly showed that GW501516-dependent interaction of PPARδ and TCPTP45 potentiated
the insulin-triggered phosphorylation of IRβ and Akt and translocation of Glut4 in C2C12
Page 19 of 55 Diabetes
20
myotubes. In fact, previous studies reported that ligand-activated PPARδ ameliorates cellular
energy homeostasis through its genomic action regulating transcription of genes including
UCP-2, UCP-3, pyruvate dehydrogenase kinase 4, carnitine palmitoyltransferase 1, and
malonyl-CoA decarboxylase in skeletal muscle (13,22-25). Thus, the possibility remains that
the effects of PPARδ activation on the insulin signaling may be attributed to their
transcriptional regulation of multiple genes rather than to direct interaction of PPARδ and
TCPTP45 in C2C12 myotubes. Further studies are necessary to clarify the exact molecule(s)
associated with PPARδ-mediated insulin signaling in muscle.
Consistent with the in vitro data, mice exposed to GW501516 for as little as 30 min
showed enhanced insulin-stimulated phosphorylation of IRβ and Akt in liver, skeletal muscle,
and adipose tissue. This GW501516-mediated enhancement in insulin signaling and glucose
homeostasis, which occurred even in HFD-fed obese mice, was accompanied by greater
interaction between PPARδ and TCPTP45, indicating that these in vivo effects of GW501516
are dependent on the association between PPARδ with TCPTP45, as in the cell models. To
date, a number of studies have shown that activation of PPARδ regulates insulin signaling by
regulating the expression of genes involved in lipid and glucose homeostasis. However, the
present study implies that PPARδ has multiple modes of action, and can enhance insulin
signaling through an interaction with TCPTP45, which we characterized as a non-genomic
action. These findings may suggest novel alternative future therapeutic strategies for
disorders related to defective insulin signaling.
Page 20 of 55Diabetes
21
Acknowledgments
Funding. This work was supported in part by the Basic Science Research Program through
the National Research Foundation of Korea (NRF), funded by the Ministry of Science, ICT
and future Planning (NRF-2017R1A2A2A05001249 and 2015R1A5A1009701), and by the
Next-Generation BioGreen 21 Program (no. PJ01122201), Rural Development
Administration, Republic of Korea.
Conflict of Interest statement. No potential conflicts of interest relevant to this article
were reported.
Author contributions. T.Y. and H.G.S. conceived and designed the experiments; T.Y.,
S.A.H., W.J.L., S.I.H., J.P., J.S.H., J.H., H.S., S.G.H., C.L., and D.W.H. performed the
experiments; T.Y., K.S.P., and H.G.S. analyzed the results and wrote the manuscript. T.Y and
H.G.S is the guarantor of this work and, as such, had full access to all the data in the study
and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Page 21 of 55 Diabetes
22
References
1. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism.
Nature 2001;414:799-806.
2. White MF. The IRS-signalling system: a network of docking proteins that mediate insulin
action. Mol Cell Biochem 1998;182:3-11.
3. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance
and type 2 diabetes. Nature 2006;444:840–846.
4. Bourdeau A, Dubé N, Tremblay ML. Cytoplasmic protein tyrosine phosphatases,
regulation and function: the roles of PTP1B and TC-PTP. Curr Opin Cell Biol 2005;17:203-
209.
5. Tiganis T. PTP1B and TCPTP--nonredundant phosphatases in insulin signaling and
glucose homeostasis. FEBS J 2013;280:445-458.
6. Galic S, Hauser C, Kahn BB, et al. Coordinated regulation of insulin signaling by the
protein tyrosine phosphatases PTP1B and TCPTP. Mol Cell Biol 2005; 25:819-829.
7. Cool DE, Tonks NK, Charbonneau H, et al. cDNA isolated from a human T-cell library
encodes a member of the protein-tyrosine-phosphatase family. Proc Natl Acad Sci U S A
1989;86:5257-5261.
8. Lorenzen JA, Dadabay CY, Fischer EH. COOH-terminal sequence motifs target the T cell
protein tyrosine phosphatase to the ER and nucleus. J Cell Biol 1995;131:631-643.
9. Lam MH, Michell BJ, Fodero-Tavoletti MT, et al. Cellular stress regulates the
nucleocytoplasmic distribution of the protein-tyrosine phosphatase TCPTP. J Biol Chem
2001;276:37700-37707.
10. Fukushima A, Loh K, Galic S, et al. T-cell protein tyrosine phosphatase attenuates
STAT3 and insulin signaling in the liver to regulate gluconeogenesis. Diabetes
2010;59:1906-1914.
11. Yamamoto T, Sekine Y, Kashima K, et al. The nuclear isoform of protein-tyrosine
phosphatase TC-PTP regulates interleukin-6-mediated signaling pathway through STAT3
dephosphorylation. Biochem Biophys Res Commun 2002;297:811-817.
12. White AT, LaBarge SA, McCurdy CE, et al. Knockout of STAT3 in skeletal muscle does
not prevent high-fat diet-induced insulin resistance. Mol Metab 2015;4:569-575.
13. Neels JG, Grimaldi PA. Physiological functions of peroxisome proliferator-activated
receptor β. Physiol Rev 2014;94:795-858.
14. Mansour M. The roles of peroxisome proliferator-activated receptors in the metabolic
syndrome. Prog Mol Biol Transl Sci 2014;121:217-266.
15. Krogsdam AM, Nielsen CA, Neve S, et al. Nuclear receptor corepressor-dependent
repression of peroxisome-proliferator-activated receptor delta-mediated transactivation.
Biochem J 2002;363:157-165.
16. Ham SA, Kang ES, Lee H, et al. PPARδ inhibits UVB-induced secretion of MMP-1
through MKP-7-mediated suppression of JNK signaling. J Invest Dermatol. 2013;133:2593-
2600.
17. Eguchi A, Furusawa H, Yamamoto A, et al. Optimization of nuclear localization signal
for nuclear transport of DNA-encapsulating particles. J Control Release. 2005;104:507-519.
18. Tiganis T, Bennett AM, Ravichandran KS, et al. Epidermal growth factor receptor and
the adaptor protein p52Shc are specific substrates of T-cell protein tyrosine phosphatase. Mol
Cell Biol 1998;18:1622-1634.
Page 22 of 55Diabetes
23
19. Senn JJ, Klover PJ, Nowak IA, et al. Suppressor of cytokine signaling-3 (SOCS-3), a
potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem
2003;278:13740-13746.
20. Galic S, Sachithanandan N, Kay TW, et al. Suppressor of cytokine signalling (SOCS)
proteins as guardians of inflammatory responses critical for regulating insulin sensitivity.
Biochem J 2014;461:177-188.
21. Qin X, Xie X, Fan Y, et al. Peroxisome proliferator-activated receptor-delta induces
insulin-induced gene-1 and suppresses hepatic lipogenesis in obese diabetic mice.
Hepatology 2008;48:432-441.
22. Ordelheide AM, Heni M, Thamer C, et al. In vitro responsiveness of human muscle cell
peroxisome proliferator-activated receptor δ reflects donors' insulin sensitivity in vivo. Eur J
Clin Invest. 2011;41:1323-1329.
23. Lee CH, Olson P, Hevener A, et al. PPARdelta regulates glucose metabolism and insulin
sensitivity. Proc Natl Acad Sci U S A 2006;103:3444-3449.
24. Chen W, Wang LL, Liu HY, et al. Peroxisome proliferator-activated receptor delta-
agonist, GW501516, ameliorates insulin resistance, improves dyslipidaemia in monosodium
L-glutamate metabolic syndrome mice. Basic Clin Pharmacol Toxicol 2008;103:240-246.
25. Spiegelman BM, Flier JS. Obesity and the regulation of energy balance. Cell
2001;104:531-543.
26. Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nat Med
2004;10:355-361.
27. Aoyama T, Peters JM, Iritani N, et al. Altered constitutive expression of fatty acid-
metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha
(PPARalpha). J Biol Chem 1998;273:5678-5684.
28. Kersten S, Seydoux J, Peters JM, et al. Peroxisome proliferator-activated receptor alpha
mediates the adaptive response to fasting. J Clin Invest. 1998;103:1489-1498.
29. Kim JH, Kim JE, Liu HY, et al. Regulation of interleukin-6-induced hepatic insulin
resistance by mammalian target of rapamycin through the STAT3-SOCS3 pathway. J Biol
Chem 2008;283:708-715.
30. Serrano-Marco L, Rodríguez-Calvo R, El-Kochairi I, et al. Activation of peroxisome
proliferator-activated receptor-β/-δ (PPAR-β/-δ) ameliorates insulin signaling and reduces
SOCS3 levels by inhibiting STAT3 in interleukin-6-stimulated adipocytes. Diabetes
2011;60:1990-1999.
31. Serrano-Marco L, Barroso E, El-Kochairi I, et al. The peroxisome proliferator-activated
receptor (PPAR) β/δ agonist GW501516 inhibits IL-6-induced signal transducer and activator
of transcription 3 (STAT3) activation and insulin resistance in human liver cells.
Diabetologia 2012;55:743-751.
32. Loh K, Merry TL, Galic S, et al. T cell protein tyrosine phosphatase (TCPTP) deficiency
in muscle does not alter insulin signalling and glucose homeostasis in mice. Diabetologia.
2012;55:468-478.
Page 23 of 55 Diabetes
24
FIGURE LEGENDS
Figure 1―PPARδ directly interacts with TCPTP45. Primary hepatocytes (A), HepG2 cells
(B), C2C12 myotubes (C), or 3T3-L1 adipocytes (D) were treated with 100 nM GW501516
or DMSO for 45 min, and then whole-cell lysates were prepared and immunoprecipitated
with IgG or anti-PPARδ antibody. The immunoprecipitates and total lysates (input) were
subjected to immunoblot analysis with specific antibodies to detect the indicated proteins.
Two percent of each whole-cell lysate was used as the input. E: HepG2 cells stably
expressing control shRNA or shRNA targeting PPARδ were treated with 100 nM GW501516
or DMSO for 45 min. Whole-cell lysates were immunoprecipitated with IgG or anti-PPARδ
antibody and analyzed by immunoblotting. F: HepG2 cells treated with 100 nM GW501516
or DMSO for 45 min were lysed and immunoprecipitated with IgG or anti-TCPTP45
antibody. The immunoprecipitates and total lysates (input) were subjected to immunoblot
analysis. G: HEK293T cells co-transfected with Flag-hPPARδ and/or HA-hTCPTP45 for 48
h were treated with 100 nM GW501516 or DMSO for 45 min, and then whole-cell lysates
were prepared and immunoprecipitated with IgG or anti-Flag antibody.
Figure 2―PPARδ targets the bipartite nuclear localization signal of TCPTP45. Whole-cell
lysates prepared from HEK293T cells transfected with Flag-tagged hPPARδ for 48 h were
incubated with recombinant GST or GST-hTCPTP45 fusion protein (A), GST or GST-fused
deletion mutants (C), or GST or GST-fused site-directed mutants (E) immobilized to
glutathione-Sepharose 4B beads for 20 h in the presence of 100 nM GW501516 or DMSO.
Bead-bound proteins were analyzed by immunoblotting. Two percent of each whole-cell
lysate was used as the input. B: Schematic illustrations of GST-hTCPTP45 fusion protein
Page 24 of 55Diabetes
25
constructs. D: Schematic illustration of the C-terminal bipartite NLS region of TCPTP45. F:
HepG2 cells were transfected with pcDNA-HA-hTCPTP45350/378-A3
for 48 h and then
separated into nuclear (N) and cytoplasmic (C) fractions. Each fraction was then subjected to
immunoblot analysis.
Figure 3―GW501516-activated PPARδ inhibits insulin-stimulated translocation of
TCPTP45 from the nucleus to the cytoplasm. A and B: CHO-IR (A) or HepG2 cells (B) co-
transfected with Flag-PPARδ and HA-hTCPTP45D182A
for 48 h were treated with 1 µM
GSK0660 or DMSO for 30 min, and then treated with 100 nM GW501516. After a further 30
min incubation, the cells were exposed to 100 nM insulin for a final 30 min. C: HepG2 cells
stably expressing PPARδ or control shRNA were transfected with HA-hTCPTP45D182A
for 48
h and then treated with 100 nM GW501516 for 30 min. Following exposure 100 nM insulin
for a final 30 min, whole-cell lysates were immunoprecipitated and analyzed by immunoblot
analysis. Two percent of each whole-cell lysate was used as the input. D: CHO-IR cells co-
transfected with GFP-PPARδ and DsRed-hTCPTP45D182A
for 48 h were incubated with 1 µM
GSK0660 or DMSO for 30 min, and then treated with 100 nM GW501516 for 30 min
incubation. After exposure to 100 nM insulin for a final 30 min, the co-localization of
TCPTP45 with PPARδ or phosphorylated IRβ is indicated by the presence of yellow or pink
in the merged image, respectively. For phosphorylated IRβ, the fixed cells were sequentially
reacted with primary anti-phospho-IRβ antibody and Alexa Fluor 680-conjugated secondary
antibody, and then the fluorescent signals were visualized. Scale bar = 20 µm.
Figure 4―GW501516-activated PPARδ extends the duration of insulin-stimulated IRβ
phosphorylation. A: HepG2 cells were treated with 100 nM GW501516 or DMSO for 30 min,
Page 25 of 55 Diabetes
26
and then treated with or without 100 nM insulin for a further 30 min. Whole-cell lysates were
prepared and subjected to immunoblot analysis. HepG2 cells co-transfected with HA-tagged
plasmids expressing hTCPTP45 or hTCPTP45350/378-A3
(B), or hTCPTP45 or hTCPTP48 (C),
for 48 h were treated with 100 nM GW501516 or DMSO for 30 min, and then exposed to
insulin for a further 30 min. Whole-cell lysates were prepared and subjected to immunoblot
analysis. D and E: HepG2 cells (D) or primary hepatocytes (E) were transfected with or
without control siRNA or siRNA targeting hTCPTP for 48 h, and then treated with 100 nM
GW501516 or DMSO. After incubation for 30 min, the cells were treated with or without 100
nM insulin for a further 30 min. Whole-cell lysates were analyzed by immunoblotting. F:
HepG2 Cells were treated with 100 nM GW501516 or DMSO for 30 min, and then exposed
to 100 nM insulin for the indicated periods of time. G: HepG2 cells transfected with Flag-
hPPARδ for 48 h were treated with 100 nM GW501516 or DMSO for 30 min, and then
exposed to 100 nM insulin for the indicated periods of time. H: Immunoblot analyses of (F)
and (G) were quantified and represented with DMSO (black circles), GW501516 (white
circles), Flag-hPPARδ overexpression + DMSO (black triangles) and Flag-hPPARδ
overexpression + GW501516 (white triangles). Data are expressed as mean ± SE (n = 3). *p <
0.01 vs DMSO-treated group. #p < 0.01 vs DMSO-treated Flag-hPPARδ group. I-K: HepG2
cells stably expressing control shRNA (I) or shRNA targeting PPARδ (J) were treated with
100 nM GW501516 or DMSO for 30 min, and then exposed to 100 nM insulin for the
indicated periods of time. The immunoblots were then quantified and represented with
control shRNA + DMSO (black circles), control shRNA + GW501516 (white circles),
hPPARδ shRNA + DMSO (black triangles) and hPPARδ shRNA + GW501516 (white
triangles) (K). Results are expressed as mean ± SE (n = 3). *p < 0.01 vs DMSO-treated
control shRNA group. L-N: HepG2 cells stably expressing control shRNA (L) or shRNA
Page 26 of 55Diabetes
27
targeting PPARδ (M) were transfected with either pcDNA-Flag or pcDNA-Flag-hPPARδ for
48 h. The cells were treated with 100 nM GW501516 or DMSO for 30 min, and then exposed
to 100 nM insulin for a further 30 min. Immunoblots were then quantified and represented
with control shRNA (red bars) or hPPARδ shRNA (blue bars) (N). Results are expressed as
mean ± SE (n = 3). **, ##
p < 0.05.
Figure 5―The GW501516-stimulated interaction of PPARδ with TCPTP45 directly affects
the insulin receptor. A: HepG2 cells stably expressing PPARδ shRNA were co-transfected
with pcDNA-HA, pcDNA-HA-hTCPTP45, pcDNA-Flag, and/or pcDNA-Flag-hPPARδ for
48 h. The cells were treated with 100 nM GW501516 or DMSO for 30 min, and then exposed
to 100 nM insulin for a further 30 min. Whole-cell lysates were analyzed by immunoblotting.
B and C: HepG2 cells co-transfected with pcDNA-Flag-hPPARδ and pcDNA-HA-hTCPTP45
(B) or pcDNA-HA-hTCPTP45350/378-A3
(C) for 48 h were treated with 100 nM GW501516 or
DMSO for 30 min, and then exposed to 100 nM insulin for a further 30 min. Cell lysates
were then immunoprecipitated with anti-Flag antibody and analyzed by immunoblotting. D:
HepG2 cells stably expressing PPARδ shRNA were treated with 100 nM GW501516 or
DMSO for 30 min, and then exposed to 100 nM insulin for the indicated periods of time.
Whole-cell lysates were analyzed by immunoblotting. E: HepG2 cells co-transfected with
pcDNA-Flag-hPPARδ and pcDNA-HA-hTCPTP45 or pcDNA-HA-hTCPTP45350/378-A3
for 48
h were treated with 100 nM GW501516 or DMSO for 30 min, and then exposed to 100 nM
insulin for a further 6 h. Whole-cell lysates were immunoprecipitated and analyzed by
immunoblotting. F: HepG2 cells stably expressing shRNA against control or PPARδ were
treated with 100 nM GW501516 or DMSO for 30 min. Following exposure to 100 nM
insulin for 8 h, the quantity of glucose present in the glucose production medium was
Page 27 of 55 Diabetes
28
determined and represented with control shRNA (red bars) or hPPARδ shRNA (blue bars).
Results are expressed as mean ± SE (n = 3). **p < 0.05.
Figure 6―GW501516-activated PPARδ modulates downstream insulin sensitivity and
resistance through its interaction with TCPTP45. Differentiated C2C12 myotubes (A and C)
or 3T3-L1 adipocytes (B and D) were treated with 100 nM GW501516 or DMSO for 30 min
and then exposed to 100 nM insulin for the indicated periods of time. The cells were
subjected to immunoblot (A and B) or fluorescence image analysis (B and D). For Glut4
translocation assay, the fixed cells were sequentially reacted with primary anti-Glut4 antibody
and Alexa Fluor 488-conjugated secondary antibody, and then the fluorescent signals were
visualized. Nuclei were stained with PI. Scale bars = 20 µm. E: HepG2 cells treated with or
without 20 ng/ml IL-6 for 90 min were incubated with 100 nM GW501516 or DMSO for 30
min, and then exposed to 100 nM insulin for a further 30 min. The cells were lysed and
analyzed by immunoblotting. F: HepG2 cells stably expressing control shRNA or shRNA
targeting PPARδ were treated with or without 20 ng/ml IL-6 for 90 min. The cells were then
incubated with 100 nM GW501516 or DMSO for a further 30 min, and then exposed to 100
nM insulin for an additional 30 min. Whole-cell lysates were then analyzed by
immunoblotting. G and H: HepG2 cells co-transfected with pcDNA-Flag-hPPARδ and
pcDNA-HA-hTCPTP45 or pcDNA-HA-hTCPTP45350/378A3
(G), or primary hepatocytes (H)
were treated with or without 20 ng/ml IL-6 for 90 min. The cells were then incubated with
100 nM GW501516 or DMSO for a further 30 min, and then exposed to 100 nM insulin for a
final 30 min. Whole-cell lysates were immunoprecipitated and analyzed by immunoblotting.
Two percent of each whole-cell lysate was used as the input.
Page 28 of 55Diabetes
29
Figure 7―Administration of GW501516 improves in vivo insulin sensitivity and glucose
tolerance through its interaction with TCPTP45. Mice fed a ND or HFD for 10 weeks were
fasted for 14 h, and treated with 10 mg/kg GW501516 or DMSO for 30 min. Following an
intraperitoneal injection of 2 g/kg glucose or 0.5 units/kg insulin, glucose (A) or insulin (B)
tolerance tests were performed. Blood glucose was then measured and represented with ND +
DMSO (black circles), ND + GW501516 (white circles), HFD + DMSO (black triangles) and
HFD + GW501516 (white triangles). Data are expressed as mean ± SE (n = 6). *p < 0.01 vs
HFD + DMSO group. Mice fed a ND or HFD for 10 weeks were fasted for 14 h, and then
treated with 10 mg/kg GW501516 or DMSO for 30 min. Following exposure to 0.5 units/kg
insulin for 30 min, the mice were sacrificed by inhalation of CO2 gas, and then liver (C),
skeletal muscle (D), and adipose tissue (E) were removed. Tissue homogenates were prepared
and immunoprecipitated with anti-TCPTP45 antibody. The total lysates (input) and
immunoprecipitates were analyzed by immunoblotting. Two percent of each tissue lysate was
used as the input. Mice were fed a ND or HFD for 10 weeks and then starved for 14 h. They
were then treated with 10 mg/kg GW501516 (red bars) or DMSO (blue bars) for 30 min and
sacrificed. Circulating levels of insulin and glucose were determined by ELISA or
spectrometric methods using sera prepared from blood collected from the carotid artery. Data
are expressed as mean ± SE (n = 6). *, #p < 0.01,
##p < 0.05.
Page 29 of 55 Diabetes
Figure 1―PPARδ directly interacts with TCPTP45. Primary hepatocytes (A), HepG2 cells (B), C2C12 myotubes (C), or 3T3-L1 adipocytes (D) were treated with 100 nM GW501516 or DMSO for 45 min, and
then whole-cell lysates were prepared and immunoprecipitated with IgG or anti-PPARδ antibody. The
immunoprecipitates and total lysates (input) were subjected to immunoblot analysis with specific antibodies to detect the indicated proteins. Two percent of each whole-cell lysate was used as the input. E: HepG2 cells stably expressing control shRNA or shRNA targeting PPARδ were treated with 100 nM GW501516 or DMSO for 45 min. Whole-cell lysates were immunoprecipitated with IgG or anti-PPARδ antibody and analyzed by
immunoblotting. F: HepG2 cells treated with 100 nM GW501516 or DMSO for 45 min were lysed and immunoprecipitated with IgG or anti-TCPTP45 antibody. The immunoprecipitates and total lysates (input)
were subjected to immunoblot analysis. G: HEK293T cells co-transfected with Flag-hPPARδ and/or HA-hTCPTP45 for 48 h were treated with 100 nM GW501516 or DMSO for 45 min, and then whole-cell lysates
were prepared and immunoprecipitated with IgG or anti-Flag antibody.
190x142mm (300 x 300 DPI)
Page 30 of 55Diabetes
Figure 2―PPARδ targets the bipartite nuclear localization signal of TCPTP45. Whole-cell lysates prepared from HEK293T cells transfected with Flag-tagged hPPARδ for 48 h were incubated with recombinant GST or
GST-hTCPTP45 fusion protein (A), GST or GST-fused deletion mutants (C), or GST or GST-fused site-
directed mutants (E) immobilized to glutathione-Sepharose 4B beads for 20 h in the presence of 100 nM GW501516 or DMSO. Bead-bound proteins were analyzed by immunoblotting. Two percent of each whole-cell lysate was used as the input. B: Schematic illustrations of GST-hTCPTP45 fusion protein constructs. D: Schematic illustration of the C-terminal bipartite NLS region of TCPTP45. F: HepG2 cells were transfected with pcDNA-HA-hTCPTP45350/378-A3 for 48 h and then separated into nuclear (N) and cytoplasmic (C)
fractions. Each fraction was then subjected to immunoblot analysis.
135x101mm (300 x 300 DPI)
Page 31 of 55 Diabetes
Figure 3―GW501516-activated PPARδ inhibits insulin-stimulated translocation of TCPTP45 from the nucleus to the cytoplasm. A and B: CHO-IR (A) or HepG2 cells (B) co-transfected with Flag-PPARδ and HA-
hTCPTP45D182A for 48 h were treated with 1 µM GSK0660 or DMSO for 30 min, and then treated with 100
nM GW501516. After a further 30 min incubation, the cells were exposed to 100 nM insulin for a final 30 min. C: HepG2 cells stably expressing PPARδ or control shRNA were transfected with HA-hTCPTP45D182A for 48 h and then treated with 100 nM GW501516 for 30 min. Following exposure 100 nM insulin for a final 30 min, whole-cell lysates were immunoprecipitated and analyzed by immunoblot analysis. Two percent of each whole-cell lysate was used as the input. D: CHO-IR cells co-transfected with GFP-PPARδ and DsRed-hTCPTP45D182A for 48 h were incubated with 1 µM GSK0660 or DMSO for 30 min, and then treated with
100 nM GW501516 for 30 min incubation. After exposure to 100 nM insulin for a final 30 min, the co-localization of TCPTP45 with PPARδ or phosphorylated IRβ is indicated by the presence of yellow or pink in
the merged image, respectively. For phosphorylated IRβ, the fixed cells were sequentially reacted with primary anti-phospho-IRβ antibody and Alexa Fluor 680-conjugated secondary antibody, and then the
fluorescent signals were visualized. Scale bar = 20 µm.
190x142mm (300 x 300 DPI)
Page 32 of 55Diabetes
Figure 4―GW501516-activated PPARδ extends the duration of insulin-stimulated IRβ phosphorylation. A: HepG2 cells were treated with 100 nM GW501516 or DMSO for 30 min, and then treated with or without 100
nM insulin for a further 30 min. Whole-cell lysates were prepared and subjected to immunoblot analysis.
HepG2 cells co-transfected with HA-tagged plasmids expressing hTCPTP45 or hTCPTP45350/378-A3 (B), or hTCPTP45 or hTCPTP48 (C), for 48 h were treated with 100 nM GW501516 or DMSO for 30 min, and then exposed to insulin for a further 30 min. Whole-cell lysates were prepared and subjected to immunoblot analysis. D and E: HepG2 cells (D) or primary hepatocytes (E) were transfected with or without control siRNA or siRNA targeting hTCPTP for 48 h, and then treated with 100 nM GW501516 or DMSO. After
incubation for 30 min, the cells were treated with or without 100 nM insulin for a further 30 min. Whole-cell lysates were analyzed by immunoblotting. F: HepG2 Cells were treated with 100 nM GW501516 or DMSO for
30 min, and then exposed to 100 nM insulin for the indicated periods of time. G: HepG2 cells transfected with Flag-hPPARδ for 48 h were treated with 100 nM GW501516 or DMSO for 30 min, and then exposed to
100 nM insulin for the indicated periods of time. H: Immunoblot analyses of (F) and (G) were quantified and represented with DMSO (black circles), GW501516 (white circles), Flag-hPPARδ overexpression + DMSO
Page 33 of 55 Diabetes
(black triangles) and Flag-hPPARδ overexpression + GW501516 (white triangles). Data are expressed as mean ± SE (n = 3). *p < 0.01 vs DMSO-treated group. #p < 0.01 vs DMSO-treated Flag-hPPARδ group. I-K: HepG2 cells stably expressing control shRNA (I) or shRNA targeting PPARδ (J) were treated with 100 nM GW501516 or DMSO for 30 min, and then exposed to 100 nM insulin for the indicated periods of time. The
immunoblots were then quantified and represented with control shRNA + DMSO (black circles), control shRNA + GW501516 (white circles), hPPARδ shRNA + DMSO (black triangles) and hPPARδ shRNA +
GW501516 (white triangles) (K). Results are expressed as mean ± SE (n = 3). *p < 0.01 vs DMSO-treated control shRNA group. L-N: HepG2 cells stably expressing control shRNA (L) or shRNA targeting PPARδ (M) were transfected with either pcDNA-Flag or pcDNA-Flag-hPPARδ for 48 h. The cells were treated with 100
nM GW501516 or DMSO for 30 min, and then exposed to 100 nM insulin for a further 30 min. Immunoblots were then quantified and represented with control shRNA (red bars) or hPPARδ shRNA (blue bars) (N).
Results are expressed as mean ± SE (n = 3). **, ##p < 0.05.
271x320mm (300 x 300 DPI)
Page 34 of 55Diabetes
Figure 5―The GW501516-stimulated interaction of PPARδ with TCPTP45 directly affects the insulin receptor. A: HepG2 cells stably expressing PPARδ shRNA were co-transfected with pcDNA-HA, pcDNA-HA-hTCPTP45, pcDNA-Flag, and/or pcDNA-Flag-hPPARδ for 48 h. The cells were treated with 100 nM GW501516 or DMSO
for 30 min, and then exposed to 100 nM insulin for a further 30 min. Whole-cell lysates were analyzed by immunoblotting. B and C: HepG2 cells co-transfected with pcDNA-Flag-hPPARδ and pcDNA-HA-hTCPTP45
(B) or pcDNA-HA-hTCPTP45350/378-A3 (C) for 48 h were treated with 100 nM GW501516 or DMSO for 30 min, and then exposed to 100 nM insulin for a further 30 min. Cell lysates were then immunoprecipitated with anti-Flag antibody and analyzed by immunoblotting. D: HepG2 cells stably expressing PPARδ shRNA were treated with 100 nM GW501516 or DMSO for 30 min, and then exposed to 100 nM insulin for the
indicated periods of time. Whole-cell lysates were analyzed by immunoblotting. E: HepG2 cells co-transfected with pcDNA-Flag-hPPARδ and pcDNA-HA-hTCPTP45 or pcDNA-HA-hTCPTP45350/378-A3 for 48 h were treated with 100 nM GW501516 or DMSO for 30 min, and then exposed to 100 nM insulin for a further
6 h. Whole-cell lysates were immunoprecipitated and analyzed by immunoblotting. F: HepG2 cells stably expressing shRNA against control or PPARδ were treated with 100 nM GW501516 or DMSO for 30 min.
Following exposure to 100 nM insulin for 8 h, the quantity of glucose present in the glucose production medium was determined and represented with control shRNA (red bars) or hPPARδ shRNA (blue bars).
Results are expressed as mean ± SE (n = 3). **p < 0.05.
135x101mm (300 x 300 DPI)
Page 35 of 55 Diabetes
Figure 6―GW501516-activated PPARδ modulates downstream insulin sensitivity and resistance through its interaction with TCPTP45. Differentiated C2C12 myotubes (A and C) or 3T3-L1 adipocytes (B and D) were treated with 100 nM GW501516 or DMSO for 30 min and then exposed to 100 nM insulin for the indicated
periods of time. The cells were subjected to immunoblot (A and B) or fluorescence image analysis (B and D). For Glut4 translocation assay, the fixed cells were sequentially reacted with primary anti-Glut4 antibody and
Alexa Fluor 488-conjugated secondary antibody, and then the fluorescent signals were visualized. Nuclei were stained with PI. Scale bars = 20 µm. E: HepG2 cells treated with or without 20 ng/ml IL-6 for 90 min
were incubated with 100 nM GW501516 or DMSO for 30 min, and then exposed to 100 nM insulin for a further 30 min. The cells were lysed and analyzed by immunoblotting. F: HepG2 cells stably expressing
control shRNA or shRNA targeting PPARδ were treated with or without 20 ng/ml IL-6 for 90 min. The cells were then incubated with 100 nM GW501516 or DMSO for a further 30 min, and then exposed to 100 nM
insulin for an additional 30 min. Whole-cell lysates were then analyzed by immunoblotting. G and H: HepG2 cells co-transfected with pcDNA-Flag-hPPARδ and pcDNA-HA-hTCPTP45 or pcDNA-HA-hTCPTP45350/378A3 (G), or primary hepatocytes (H) were treated with or without 20 ng/ml IL-6 for 90 min. The cells were then
incubated with 100 nM GW501516 or DMSO for a further 30 min, and then exposed to 100 nM insulin for a final 30 min. Whole-cell lysates were immunoprecipitated and analyzed by immunoblotting. Two percent of
each whole-cell lysate was used as the input.
190x142mm (300 x 300 DPI)
Page 36 of 55Diabetes
Figure 7―Administration of GW501516 improves in vivo insulin sensitivity and glucose tolerance through its interaction with TCPTP45. Mice fed a ND or HFD for 10 weeks were fasted for 14 h, and treated with 10 mg/kg GW501516 or DMSO for 30 min. Following an intraperitoneal injection of 2 g/kg glucose or 0.5
units/kg insulin, glucose (A) or insulin (B) tolerance tests were performed. Blood glucose was then measured and represented with ND + DMSO (black circles), ND + GW501516 (white circles), HFD + DMSO (black triangles) and HFD + GW501516 (white triangles). Data are expressed as mean ± SE (n = 6). *p <
0.01 vs HFD + DMSO group. Mice fed a ND or HFD for 10 weeks were fasted for 14 h, and then treated with 10 mg/kg GW501516 or DMSO for 30 min. Following exposure to 0.5 units/kg insulin for 30 min, the mice were sacrificed by inhalation of CO2 gas, and then liver (C), skeletal muscle (D), and adipose tissue (E)
were removed. Tissue homogenates were prepared and immunoprecipitated with anti-TCPTP45 antibody. The total lysates (input) and immunoprecipitates were analyzed by immunoblotting. Two percent of each tissue lysate was used as the input. Mice were fed a ND or HFD for 10 weeks and then starved for 14 h.
They were then treated with 10 mg/kg GW501516 (red bars) or DMSO (blue bars) for 30 min and sacrificed. Circulating levels of insulin and glucose were determined by ELISA or spectrometric methods using sera
prepared from blood collected from the carotid artery. Data are expressed as mean ± SE (n = 6). *, #p < 0.01, ##p < 0.05.
135x101mm (300 x 300 DPI)
Page 37 of 55 Diabetes
1
SUPPLEMENTARY DATA
Materials
GSK0660 and GW501516 were purchased from Enzo Life Sciences (Farmingdale, NY, USA)
and Tocris Bioscience (Bristol, UK), respectively. Insulin, puromycin, isopropyl β-D-1-
thiogalactopyranoside (IPTG), propidium iodide (PI), mouse anti-Flag monoclonal antibody,
rabbit anti-β-actin polyclonal antibody, and HRP-conjugated goat anti-rabbit IgG antibody
were purchased from Sigma-Aldrich Co. (St. Louis, MO, USA). Recombinant human IL-6
was obtained from R&D Systems (Minneapolis, MN, USA). A monoclonal anti-HA antibody
and polyclonal antibodies specific for phospho-Akt (Ser4473), Akt, and TCPTP45 were
obtained from Cell Signaling (Beverly, MA, USA). Monoclonal antibodies specific for
PTP1B, TCPTP, phospho-STAT3 (Tyr705), STAT3, and a polyclonal rabbit anti-SOCS3
antibody were obtained from Abcam (Cambridge, MA, USA). Polyclonal antibodies specific
for phospho-IRS1 (Tyr612), IRS, and Glut4 were obtained from Millipore (Bedford, MA,
USA). A rabbit anti-phospho-IR (Tyr1162/1163) polyclonal antibody was obtained from
Invitrogen (San Diego, CA, USA). Polyclonal antibodies specific for PPARα, PPARδ, and
PPARγ, and monoclonal antibodies specific for α-tubulin, lamin B, and GST, were purchased
from Santa Cruz Biotechnology (Dallas, TX, USA). ND (4.3% fat, 67.3% carbohydrate, and
19.2% protein) were purchased from Altromin Spezialfutter GmbH & Co. (Lage, North
Rhine-Westphalia, Germany) and a HFD (24% fat, 41% carbohydrate, and 24% protein
(206.8 g/kg lard)) were purchased from Research Diets Inc. (New Brunswick, NJ, USA).
Cell culture and differentiation
The human hepatoblastoma-derived HepG2 and HEK293T cells, and mouse 3T3-L1
preadipocytes, were obtained from the Korean Cell Line Bank (Seoul, Korea), and mouse
Page 38 of 55Diabetes
2
C2C12 myoblast cells were a gift from Dr. Eun Jung Cho (School of Pharmacy,
Sungkyunkwan University, Suwon, Korea). All were maintained in Dulbecco’s modified
Eagle’s medium (DMEM). CHO-IR cells were kindly provided by Dr. Deok-Bae Park
(Department of Medicine, Jeju National University, Jeju, Korea) and cultured in Ham’s F-12
medium. The primary hepatocytes from mouse were isolated by collagenase perfusion
method as described previously (1) and then cultured in DMEM/F-12 medium supplemented
with 0.1 µM dexamethasone, 10 mM nicotinamide, 1% insulin-transferrin-selenium premix,
and growth factors. All cells were maintained in medium containing antibiotics and 10% fetal
bovine serum at 37 °C in a humidified atmosphere of 5% CO2 and 95% air. For the
differentiation of C2C12 myoblasts, cells were grown to near 100% confluency in normal
DMEM, as described above, and then incubated in DMEM containing 2% horse serum for 3
days to induce differentiation into myotubes, as described previously (2). To differentiate
3T3-L1 preadipocytes, cells were cultured to near 100% confluence, then incubated in
DMEM containing MDI (250 nM dexamethasone, 500 µM 3-isobutyl-1-methylxanthine, and
200 nM insulin) solution for 10 days to induce differentiation into adipocytes, as described
previously (3). For further analysis, the myotubes, adipocytes, and HepG2 cells were
incubated in serum-free DMEM for 16 h, and then treated with the indicated reagents for the
indicated periods of time.
Plasmid construction and transfection
To express epitope-tagged proteins, Flag- or HA-tagged pcDNA3.1 vector was used
(Stratagene, La Jolla, CA, USA). First-strand synthesis of full-length cDNAs for human
PPARδ (GenBank accession no. NM_006238.4), mouse PPARδ (GenBank accession no.
NM_011145.3), mouse PPARα (GenBank accession no. NM_011144.6), mouse PPARγ
Page 39 of 55 Diabetes
3
(GenBank accession no. NM_001127330.2), human TCPTP48 (GenBank accession no.
NM_002828.3), human TCPTP45 (GenBank accession no. NM_080422.2), and mouse
TCPTP45 (GenBank accession no. NM_008977.3) was performed using 1 µg of total RNA
and TOPscript RT DryMIX kit (Enzynomics, Seoul, Korea). Reverse transcription was
followed by 25 cycles of PCR amplification using the primers 5ʹ-
CTGAAGCTTATGGAGCAGCCACAGGAG-3ʹ and 5ʹ-
AGTTCTAGATTAGTACATGTCCTTGTA-3ʹ (human PPARδ), 5ʹ-
GCCAAGCTTATGGAACAGCCACAGGAG-3ʹ and 5ʹ-
GCCGATATCTTAGTACATGTCCTTGTAG-3ʹ (mouse PPARδ), 5ʹ-
GCCAAGCTTATGGTGGACACAGAGAG-3ʹ and 5ʹ-
GCCGATATCTCAGTACATGTCTCTGTAG-3ʹ (mouse PPARα), 5ʹ-
GCCAAGCTTATGGTGGACACAGAGAG-3ʹ and 5ʹ-
GCCGATATCTCAGTACATGTCTCTGTAG-3ʹ (mouse PPARγ), 5ʹ-
CTGGGATCCATGCCCACCACCATCGAG-3ʹ and 5ʹ-
AGTCTCGAGTTATAGGGCATTTTGCTG-3ʹ (human TCPTP48), 5ʹ-
CTGGGATCCATGCCCACCACCATCGAG-3ʹ and 5ʹ-
AGTGATATCTTAGGTGTCTGTCAATCT-3ʹ (human TCPTP45), and 5ʹ-
CTGGGATCCATGTCGGCAACCATCGAG-3ʹ and 5ʹ-
AGTCTCGAGTTAGGTGTCTGTCAATCT-3ʹ (mouse TCPTP45). Each PCR product was
digested with appropriate restriction enzymes, and ligated into the similarly digested
pcDNA3.1/Flag or pcDNA3.1/HA vector to yield the expression vectors pcDNA3.1-Flag-
hPPARδ, pcDNA3.1-Flag-mPPARδ, pcDNA3.1-Flag-mPPARα, pcDNA3.1-Flag-mPPARγ,
pcDNA3.1-HA-hTCPTP48, pcDNA3.1-HA-hTCPTP45, and pcDNA3.1-HA-mTCPTP45,
respectively. The pMT2-hTCPTP45D182A
plasmid was a gift from Dr. Nicholas K. Tonks
Page 40 of 55Diabetes
4
(Cold Spring Harbor Laboratory, New York, USA). For GST-fusion proteins, full-length
hTCPTP45 cDNA was cloned into the BamHI and XhoI sites of the pGEX4T-1 vector (GE
Healthcare Life Sciences, PA, USA) to yield the GST-fusion vector pGEX4T-1-hTCPTP45.
Deletion mutants of GST-hTCPTP45 were constructed by PCR amplification of fragments
from pGEX4T-1-hTCPTP45. These fragments were digested with BamHI/XhoI and ligated
into the similarly digested pGEX4T-1 vector, generating GST-hTCPTP45 (D1) and GST-
hTCPTP45 (D2). Site-directed mutants of GST-hTCPTP45, GST-hTCPTP45350-A3
(R350A,
K351A, and R351A), GST-hTCPTP45378-A3
(K378A, R379A, and K380A), and GST-
hTCPTP45350/378-A3
(R350A, K351A, R351A, K378A, R379A, and K380A) were created
using a QuikChange Site-Directed Mutagenesis Kit (Stratagene) and pGEX4T-1-hTCPTP45
plasmid. HA-tagged hTCPTP45350/378-A3
was generated by PCR amplification of GST-
hTCPTP45350/378-A3
using the primers 5ʹ- CTTAAGCTTATGAGCGATAACGATGAC-3ʹ and
5ʹ-CCATCTAGATCAGCTCTCGCTTTCCCCTT-3ʹ. The PCR product was digested with
HindIII and XbaI, and ligated into the similarly digested pcDNA3.1/HA vector to yield the
expression vector pcDNA3.1-HA-hTCPTP45350/378-A3
. For the localization assay, GFP-
hPPARδ, DsRed-hTCPTP45D182A
, and DsRed-hTCPTP48D182A
were generated using pEGFP-
C1 and pDsRed-Express-C1 (Clontech Laboratories, Inc., CA, USA). All recombinant
plasmids were sequenced and verified. HepG2 and HEK293T cells were transfected with the
indicated plasmids using Genefectin (Genetrone Biotech, Gwangmyeong, Korea) for 6 h, and
the existing medium was then replaced with fresh medium. After incubation for an additional
48 h, the cells were stimulated with the indicated reagents for the specified period of time.
Bacterial expression of GST-fusion proteins and GST pull-down assay
The binding of PPARδ to TCPTP45 was assessed using bacterially expressed GST-fusion
Page 41 of 55 Diabetes
5
proteins essentially as previously described (4). Briefly, mouse full-length GST-hTCPTP45
(FL), GST-hTCPTP45 (D1), GST-hTCPTP45 (D2), GST-hTCPTP45350-A3
, GST-
hTCPTP45378-A3
, and GST-hTCPTP45350/378-A3
cloned into the pGEX4T-1 vector were
transformed into BL21 competent cells. Clones were cultured in LB medium containing 50
µg/ml ampicillin, and the expression of GST or GST-fused hTCPTP45 was initiated with 0.5
mM IPTG at an OD600 of approximately 0.6 for 18 h at 18 °C. The bacterial pellets were
collected by centrifugation at 10,000 × g for 15 min and then resuspended in lysis buffer (30
mM Tris-Cl, 1% NP-40, protease inhibitors, 1 mM DTT, 0.1 mM NaCl, pH 7.5). The
bacterial lysates were sonicated for 3 × 1 min, and the soluble fraction was obtained by
centrifugation at 12,000 rpm for 30 min. Because the GST-fusion proteins were largely in the
soluble fraction, the supernatants were mixed with glutathione-Sepharose 4B beads (GE
Healthcare Life Sciences) for 4 h to immobilize the GST-fusion proteins. To identify binding
of PPARδ to TCPTP45, the immobilized GST-fusion proteins were mixed with cell lysates
overexpressing PPARδ in the presence or absence of GW501516 overnight at 4 °C.
Following extensive washing with phosphate-buffered saline (PBS), the interaction between
PPARδ and TCPTP45 was evaluated by immunoblotting.
Co-immunoprecipitation and immunoblot analysis
Cell and tissue lysates were prepared using PRO-PREP Protein Extraction Solution (iNtRON
Biotechnology, Seoul, Korea) and then pre-cleared with protein G Sepharose™ 4 Fast Flow
(GE Healthcare Life Sciences, Buckinghamshire, UK). Pre-cleared lysates were mixed with
the specified antibodies (1 µg) or relevant IgG overnight at 4 °C, and then mixed with protein
G Sepharose for 4 h. After washing with PBS, proteins were separated from the Sepharose
Page 42 of 55Diabetes
6
beads by boiling in 2×SDS gel-loading buffer and resolved on 10% SDS-polyacrylamide gels.
The immunoprecipitates and total lysates (input) were subjected to immunoblot analysis with
the specified antibodies, and immunoreactive bands were detected using West-ZOL Plus
(iNtRON Biotechnology), as previously described (4). Two percent of each whole-cell lysate
was used as the input.
Creation of HepG2 cells stably expressing shRNA targeting PPARδδδδ
PPARδ-silenced HepG2 cells were created by infection with lentiviral particles expressing
PPARδ (TRCN0000350974, MISSION Lentiviral Transduction Particles, Sigma-Aldrich) or
a control containing a puromycin resistance gene (pLKO.1-puro Non-Target shRNA Control
Transduction Particles, Sigma-Aldrich). The viral particles were used to infect HepG2 cells
according to the manufacturer’s instructions, and positive cells were selected using 2 µg/ml
puromycin. The efficacy of PPARδ silencing was confirmed by immunoblot analysis.
Gene silencing with siRNA
Gene silencing with specific siRNAs was performed essentially as previously described (5).
Briefly, HepG2 cells were transfected with transfection-ready control siRNA (Ambion,
Austin, TX, USA), human PPARδ-targeting siRNA (Ambion), and human TCPTP-targeting
siRNA designed against the sequences 5ʹ-GGUCCACUUCCUAACACAUGCdTdT-3ʹ and
5ʹ-GCAUGUGUUAGGAAGUGGACCdTdT-3ʹ of the PTPN2 mRNA, and human PTP1B-
targeting siRNA designed against the sequences 5ʹ-UAGGUACAGAGACGUCAGUdTdT-3ʹ
and 5ʹ-ACUGACGUCUCUGUACCUAdTdT-3ʹ of the PTPN1 mRNA, in serum-free DMEM.
The siRNAs against TCPTP and PTP-1B were synthesized by Bioneer (Daejeon, Korea).
Page 43 of 55 Diabetes
7
Following incubation for 6 h, the medium was replaced with fresh medium containing 10%
FBS and the cells were incubated for an additional 24 h. The cells were then serum-starved
for 18 h and treated with the specified reagents for the indicated period of time, after which
the effects of gene silencing were assessed.
Fluorescence confocal laser microscopy
Fluorescence images were analyzed as described previously (4). Briefly, 1 × 104 cells were
seeded on cover-glasses in 35 mm dishes (SPL Life Sciences, Seoul, Korea), and then
transfected with GFP-hPPARδ and DsRed-hTCPTP45D182A
or DsRed-hTCPTP48D182A
using
Genefectin (Genetrone Biotech). Forty-eight hours after transfection, cells were treated with
insulin, GW501516, and/or GSK0660 for the indicated periods of time. The cells were then
incubated with 2 µg/ml DAPI (4′,6-diamidino-2-phenylindole) solution for 10 min at room
temperature. Following staining, the cover-glasses were mounted and examined using an
Olympus FV-1000 confocal laser fluorescence microscope (Olympus, Tokyo, Japan). The line
intensity profiles were obtained using Image J 1.5 (imagej.nih.gov/ij/) software.
Glut4 translocation assay
C2C12 myotubes and 3T3-L1 adipocytes seeded on 35 mm cover-glasses in dishes (SPL Life
Sciences) were incubated in serum-free DMEM for 16 h and then stimulated with 100 nM
insulin in the presence or absence of GW501516. After treatment for 30 min or 6 h, the cells
were fixed using neutral buffered 4% formaldehyde solution for 7 min. After
permeabilization with PBS containing 0.1% Tween-20 for 3 min, the fixed cells were
incubated overnight at 4 °C with 1:200 anti-Glut4 antibody. Secondary goat anti-rabbit IgG
conjugated to Alexa Fluor 488 (Sigma) was applied for 2 h at room temperature, and then the
Page 44 of 55Diabetes
8
cells were incubated for 10 min in PI solution. The subcellular localization of Glut4 was
evaluated in single cells using an Olympus FV-1000 confocal laser fluorescence microscope.
Hepatocyte glucose production assay
The glucose content of media was measured according to a previously described method (1).
Briefly, HepG2 cells seeded on a 96-well plate were incubated in serum-free DMEM for 16 h
and then the medium was replaced with glucose production medium (glucose- and phenol
red-free DMEM supplemented with 20 mM sodium lactate and 2 mM sodium pyruvate).
HepG2 cells were treated with 100 nM GW501516 or vehicle for 30 min, and then exposed
to 100 nM insulin for 8 h. The glucose concentration in the conditioned medium was
measured using a QuantiChrom Glucose assay kit (Bioassay Systems, CA, USA) and
normalized to total protein content.
Animal study
Male ICR mice (4-week-old, 15–20 g) were purchased from Orient Bio (Seongnam, Korea)
and maintained in pathogen-free environmental conditions on a 12 h light-dark cycle at 22 ±
2 °C. All procedures were approved by the Institutional Animal Care and Use Committee of
Konkuk University (approval number: KU16144). After 1 week of acclimation, the mice
were divided into two groups, and were fed either a ND (Altromin Spezialfutter GmbH & Co.,
Lage, Germany) or a HFD (Research Diets, Inc. NJ, USA) for 10 weeks, during which water
and diet were available ad libitum. The ND contained 4.3% fat, 67.3% carbohydrate, and 19.2%
protein, whereas the HFD was composed of 24% fat, 41% carbohydrate, and 24% protein
(206.8 g/kg lard). Body mass was measured once a week.
Page 45 of 55 Diabetes
9
Serum analysis
Serum levels of insulin, glucose, and IL-6 were analyzed in circulating blood samples
obtained from ND or HFD-fed mice that had been starved for 14 h and treated with 10 mg/kg
GW501516 or DMSO for 30 min. Blood was collected, allowed to clot for 2 h at room
temperature, and centrifuged for 20 min at 4,000 rpm, as described previously (4). Serum
glucose was determined using an OneTouch automatic glucose monitor (LifeScan, Inc.).
Serum levels of insulin and IL-6 were measured using a Ultra Sensitive Mouse Insulin ELISA
Kit (Morinaga Institute of Biological Science, Inc., Yokohama, Japan) and a Mouse IL-6
Platinum ELISA Kit (eBioscience, San Diego, CA, USA), respectively.
Page 46 of 55Diabetes
10
Supplementary Figure 1―Ligand-dependent interaction of PPARδ with TCPTP45. A:
HepG2 cells were transfected with control shRNA or shRNA targeting PPARδ, and the stable
transfectants were selected in the presence of 2 µg/ml hygromycin. The transfectants were
lysed and immunoblotted to determine the expression levels of PPARδ and β-actin. B:
HEK293T cells co-transfected with Flag-hPPARδ and/or HA-hTCPTP45 for 48 h were
treated with 100 nM GW501516 or DMSO for the indicated periods of time, and then whole-
cell lysates were prepared and immunoprecipitated with anti-Flag antibody. Immunoblot
analysis was performed using the immunoprecipitates and total lysates (input). C: HEK293T
cells co-transfected with pcDNA-Flag, pcDNA-Flag-mPPARα, pcDNA-Flag-mPPARδ, or
pcDNA-Flag-mPPARγ in the presence of pcDNA-HA-mTCPTP45 for 48 h were treated with
10 µM WY-14643 (PPARα activator), 100 nM GW501516 (PPARδ activator), or 10 µM
rosiglitazone (PPARγ activator) for 45 min, and then whole-cell lysates were prepared and
immunoprecipitated with anti-Flag antibody. Immunoblot analysis was performed using the
immunoprecipitates and total lysates (input). Two percent of each whole-cell lysate was used
as the input.
Page 47 of 55 Diabetes
11
Supplementary Figure 2―Interaction of PPARδ with TCPTP in subcellular fractions. A:
HepG2 cells were treated with 100 nM GW501516 or DMSO for 45 min, and then whole-cell
lysates were prepared and immunoprecipitated with IgG or anti-PPARδ antibody. The
immunoprecipitates and total lysates (input) were subjected to immunoblot analysis. B and C:
HepG2 cells were treated with 100 nM GW501516 or DMSO for 45 min, and then separated
into nuclear (B) and cytoplasmic (C) fractions. Each subcellular fraction was
immunoprecipitated with anti-PPARδ antibody. D: Schematic illustration of the C-terminal
bipartite NLS region of TCPTP45 replaced with canonical SV40 large T antigen NLS
(PKKKRKV) by site-directed mutation to yield mutant TCPTP45350/378-SV40
. E: HepG2 cells
were transfected with HA-hTCPTP45350/378-SV40
for 48 h and then separated into nuclear (N)
and cytoplasmic (C) fractions. Each fraction was analyzed by immunoblot. F: HepG2 cells
co-transfected with Flag-hPPARδ and HA-hTCPTP45350/378-SV40
for 48 h were treated with
100 nM GW501516 or DMSO for 30 min. Following exposure to 100 nM insulin for 30 min,
Page 48 of 55Diabetes
12
the cells were lysed and immunoprecipitated with anti-Flag antibody. The
immunoprecipitates and total lysates (input) were subjected to immunoblot analysis. Two
percent of each whole-cell lysate was used as the input.
Page 49 of 55 Diabetes
13
Supplementary Figure 3―Localization of PPARδ and TCPTP45 or TCPTP48 complexes. A
and B: CHO-IR cells co-transfected with GFP-hPPARδ and DsRed-hTCPTP45D182A
(A) or
DsRed-hTCPTP48D182A
(B) for 48 h were treated with 100 nM GW501516 or DMSO for 30
min, and then exposed to 100 nM insulin or vehicle. After a further incubation for 30 min, the
fluorescence of each fusion protein was visualized using confocal laser fluorescence
microscopy. The co-localization of PPARδ and TCPTP45 or TCPTP48 is indicated by the
presence of white in the merged image. Representative fluorescence intensity profiles across
the cell were obtained from the merged images through the white arrows. Scale bar = 20 µm.
Page 50 of 55Diabetes
14
Supplementary Figure 4―Differential effects of PPAR ligands on the insulin-stimulated
phosphorylation of IRβ. A: HepG2 cells transfected with or without control siRNA or siRNA
targeting PTP1B for 48 h were treated with 100 nM GW501516 or DMSO for 30 min, and
then exposed to 100 nM insulin or vehicle for a further 30 min. Whole-cell lysates were
analyzed by immunoblotting to detect the indicated proteins using specific antibodies. B:
HepG2 cells were transfected with pcDNA-Flag or pcDNA-Flag-hPPARδ for 48 h and then
lysed and immunoblotted with anti-PPARδ and anti-β-actin antibodies to detect PPARδ and
β-actin, respectively. C and D: HepG2 cells transfected with pcDNA-Flag (C) or pcDNA-
Flag-hPPARδ (D) for 48 h were treated with 100 nM GW501516 or DMSO for 30 min and
then exposed to 100 nM insulin for the indicated periods of time. Immunoblot analysis was
performed using whole-cell lysates to detect the indicated proteins using specific antibodies.
E and F: HepG2 cells treated with 10 µM WY-14643 (E) or 10 µM rosiglitazone (F), specific
ligands for PPARα and PPARγ, for 30 min were exposed to 100 nM insulin or vehicle for the
indicated time periods. The cells were then lysed and analyzed by immunoblotting.
Page 51 of 55 Diabetes
15
Supplementary Figure 5―Involvement of TCPTP45 in the PPARδ-mediated potentiation of
insulin signaling. A: HepG2 cells stably expressing control shRNA were transfected with
pcDNA-HA or pcDNA-HA-hTCPTP45 for 48 h. The cells were then treated with 100 nM
GW501516 or DMSO for 30 min, and exposed to 100 nM insulin for a further 30 min.
Whole-cell lysates were prepared and subjected to immunoblot analysis using specific
antibodies. B: HepG2 cells stably expressing control shRNA were treated with 100 nM
GW501516 or DMSO for 30 min, and then exposed to 100 nM insulin for the indicated
periods of time. Whole-cell lysates were prepared and subjected to immunoblot analysis.
Page 52 of 55Diabetes
16
Supplementary Figure 6―PPARδ-mediated modulation of insulin signaling. A and B:
C2C12 myotubes (A) or 3T3-L1 adipocytes (B) were treated with 100 nM GW501516 or
DMSO for 30 min. Following exposure to 100 nM insulin for 30 min, the cells were lysed
and sequentially analyzed by immunoprecipitation and immunoblotting. C: C2C12 myotubes
co-transfected with Flag-hPPARδ and HA-hTCPTP45 or HA-hTCPTP45350/378-A3
for 48 h
were treated with 100 nM GW501516 or DMSO for 30 min, and then exposed to 100 nM
insulin for a further 30 min. Whole-cell lysates were prepared and analyzed by
Page 53 of 55 Diabetes
17
immunoprecipitation and immunoblotting. Two percent of each whole-cell lysate was used as
the input. D: HepG2 cells transfected with siRNA were treated with or without 20 ng/ml IL-6.
Following treatment for 90 min, the cells were incubated with 100 nM GW501516 or DMSO
for 30 min, and then exposed to 100 nM insulin for a further 30 min. The cells were lysed and
subjected to immunoblot analysis.
Page 54 of 55Diabetes
18
Supplementary Figure 7―In vivo effects of GW501516 in mice fed a normal or high-fat
diet. A: Time-dependent changes in body mass of mice fed a ND (black circles) or HFD
(white circles) for 10 weeks. Data are expressed as mean ± SE (n = 6). *p < 0.01 and
**p <
0.05 vs ND group. B: Mice fed a ND or HFD for 10 weeks were starved for 14 h and then
treated with 10 mg/kg GW501516 (red bars) or DMSO (blue bars) for 30 min. Circulating
levels of IL-6 were measured by ELISA using sera prepared from blood collected from the
carotid artery. Data are expressed as mean ± SE (n = 4). **p < 0.05.
Page 55 of 55 Diabetes
19
References
1. Choi D, Oh KJ, Han HS, et al. Protein arginine methyltransferase 1 regulates hepatic
glucose production in a FoxO1-dependent manner. Hepatology 2012;56:1546-1556.
2. Song, TY, Yang, JH, Park, JY, et al. The role of histone chaperones in osteoblastic
differentiation of C2C12 myoblasts. Biochem Biophys Res Commun. 2012;423:726-732.
3. Zebisch, K, Voigt V, Wabitsch M, et al. M. Protocol for effective differentiation of 3T3-L1
cells to adipocytes. Anal Biochem. 2012;425:88-90.
4. Hwang JS, Choi HS, Ham SA, et al. Deacetylation-mediated interaction of SIRT1-HMGB1
improves survival in a mouse model of endotoxemia. Sci Rep 2015;5:15971.
5. Yoo T, Ham SA, Hwang JS, et al. Peroxisome proliferator-activated receptor δ inhibits
Porphyromonas gingivalis lipopolysaccharide-induced activation of matrix
metalloproteinase-2 by downregulating NADPH oxidase 4 in human gingival fibroblasts.
Mol Oral Microbiol 2016;31:398-409.
Page 56 of 55Diabetes
Recommended